|
Abstract:
|
Data on TRD patients treated with treatment-as-usual (TAU) or adjunctive vagus nerve stimulation (VNS+TAU) in a clinical trial was analyzed to understand whether a minimum 50% drop in MADRS score (typically used as threshold for a response) was necessary to achieve clinically meaningful improvement in Quality of life. The analysis showed that depending on the therapy received, a patient may experience clinically meaningful improvement in Quality of life with a drop in MADRS score of as low as 34%. In this talk, we discuss how simple estimation approach was more effective than a hypothesis testing approach in reaching this conclusion and getting the work accepted in a prestigious psychiatry journal.
|
